Table 2.
The optimal SRM conditions of candidate peptides obtained by the OAO procedure, and the S/N achievable in human liver cytosol
| Optima of SRM conditions | ||||
|---|---|---|---|---|
| Candidate Peptide | cS/N | |||
| Optimal transition |
aTL (V) |
bProduct ion /Optimal CE in eV |
||
| CBR1 | ||||
| d#TNFFGTR (T1-1) | 421.7→627.3 | 120 | 627.3/23; 216.1/27; 480.3/19; 363.2/27; 333.3/27 |
3.4E3 |
| e*DVCTELLPLIK(T1-2) | 650.8→831.3 | 115 | 831.3/24; 470.4/29; 1154.6/24; 543.8/34; 718.4/29 |
1.6E4 |
| #SCSPELQQK (T1-3) | 538.7→829.5 | 100 | 829.5/25; 281.1/29; 742.4/21; 516.4/29; 248.1/29 |
6.5E2 |
| GIGLAIVR (T1-4) | 399.8→458.4 | 105 | 458.4/19; 628.4/19; 341.2/23; 171.0/27; 387.4/23 |
2.1E3 |
| *LFSGDVVLTAR(T1-5) | 589.3→917.5 | 130 | 917.5/21; 559.4/29; 460.4/25; 619.4/21; 831.5/29 |
6.3E4 |
| CBR3 | ||||
|
#EYGGLNVLVNNAAV AFK (T3-1) |
890.0→1064.5 | 150 | 1064.5/27; 715.4/32; 834.5/27; 933.5/32; 1414.6/22 |
7.7E4 |
| *VVNISSLQCLR(T3-2) | 644.8→863.3 | 115 | 863.3/29; 776.4/24; 1090.7/19; 312.8/24; 576.1/29 |
1.5E4 |
| LGVTVLSR(T3-3) | 422.8→575.4 | 90 | 575.4/23; 375.3/27; 674.5/19; 470.3/23; 474.5/27 |
2.6E4 |
| *VALVTGANR(T3-4) | 450.8→730.4 | 115 | 730.4/21; 518.3/25; 417.3/29; 617.5/21; 383.3/33 |
2.1E4 |
|
#AFENCSEDLQER(T3- 5) |
749.3→876.4 | 155 | 876.4/24; 432.1/24;660.1/29; 218.9/34; 640.5/24 |
3.9E2 |
| GIGLAIAR(T3-6) | 385.7→600.4 | 105 | 600.4/19; 430.2/19; 341.2/23; 359.3/23; 412.3/27 |
2.7E3 |
| #QFSGDVVLTAR(T3-7) | 596.8→917.5 | 130 | 917.5/21; 460.4/25; 559.4/29; 658.5/21; 347.3/29 |
3.8E4 |
a
Tube lens voltage.
b
The fragments were sorted in the order of the most abundant to least abundant; only the top two most abundant transitions were used for analysis;
c
The S/N for the most sensitive transition, evaluated by spiking 1 µg/mL proteins into a pooled human liver cytoso preparation;
d
“#” denotes the peptide was not stable as evaluated by the stability examination (cf. Fig. 5).
e
“*” denotes that the peptide was chosen as a signature peptide (SP).